Safety and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine According to Number and Timing of Primary Series Doses.
Mary Kline, Anne L Wyllie, Kathleen McElwee et al.
✦ AI-curated · Sources linked
In 30 seconds
This descriptive post hoc analysis of two phase III randomised trials assessed PCV20 safety and immune responses in healthy infants receiving 2 + 1 or 3 + 1 schedules. Within the 2 + 1 schedule, infants primed at 3 and 5 months had higher serotype-specific IgG responses across all 20 vaccine serotypes than those primed at 2 and 4 months; responses were comparable to those with PCV13 at 2 and 4 months. Post-toddler-dose IgG levels were similar to those observed with a 3 + 1 schedule, regardless of primary-dose timing. PCV20 was safe and well tolerated in both timing subgroups.
Key findings
- PCV20 priming at 3 and 5 months was associated with higher IgG responses across all 20 serotypes than priming at 2 and 4 months.
- Responses after PCV20 at 3 and 5 months were comparable to PCV13 responses at 2 and 4 months.
- Post-toddler-dose IgG levels with the PCV20 2 + 1 schedule were similar to those with a 3 + 1 schedule, regardless of primary-dose timing.
- PCV20 was safe and well tolerated in both primary-dose timing subgroups.
Why it matters
The findings indicate that the timing of infant PCV20 priming may influence measured immune responses, while booster responses after the toddler dose were similar across the schedules examined. This is relevant when interpreting immunogenicity data across dosing regimens, but the analysis reports immune responses rather than comparative clinical protection.
What to keep in mind
This was a descriptive post hoc analysis; the schedule comparisons were not presented as a direct randomised comparison.